Haiqin Wang

Hunan Province Key Laboratory Of Basic And Applied Hematology
Changsha, 410011, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

The function and mechanism of clinical trial agent CPI-613 in multiple myeloma.

The function and mechanism of clinical trial agent CPI-613 in multiple myeloma.

Journal: Biochemical pharmacology
Published: July 20, 2024

Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression.

Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression.

Journal: Oncogene
Published: July 18, 2024

Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic target.

Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic target.

Journal: Carcinogenesis
Published: March 07, 2024

Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma.

Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma.

Journal: Cancers
Published: January 15, 2023

Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo.

Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-κB signaling in vivo.

Journal: Biomaterials
Published: December 30, 2022

Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.

Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.

Journal: Cancer letters
Published: May 11, 2022

Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.

Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.

Journal: Cancer letters
Published: February 14, 2022

Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1.

Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1.

Journal: Oncogene
Published: June 07, 2021

Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells.

Identification and Characterization of Multiple Myeloma Stem Cell-Like Cells.

Journal: Cancers
Published: May 24, 2021

Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.

Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.

Journal: Cancer letters
Published: March 20, 2021

Protein mass spectrometry reveals lycorine exerting anti-multiple-myeloma effect by acting on VDAC2 and causing mitochondrial abnormalities.

Protein mass spectrometry reveals lycorine exerting anti-multiple-myeloma effect by acting on VDAC2 and causing mitochondrial abnormalities.

Journal: Biotechnology letters
Published: May 11, 2020

The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.

The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.

Journal: British journal of haematology
Published: December 24, 2019
Showing 1-12 of 16

Last Updated: 09/26/2026